Braveheart Bio (NASDAQ:BRVE) Director Purchases 1,940,000 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) Director Erez Chimovits bought 1,940,000 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $34,920,000.00. Following the acquisition, the director owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This trade represents a 19.47% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Braveheart Bio Stock Down 9.2%

Shares of NASDAQ BRVE traded down $2.52 during mid-day trading on Tuesday, hitting $25.01. 724,651 shares of the company were exchanged, compared to its average volume of 569,084. Braveheart Bio, Inc. has a 1-year low of $24.61 and a 1-year high of $32.00.

Get Braveheart Bio alerts:

About Braveheart Bio

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

Further Reading

• Five stocks we like better than Braveheart Bio
• Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
• AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
• NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
• Apple’s Next iPhone Could Test How Much Pricing Power Is Left

Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.